Is genetic screening for hemochromatosis worthwhile?

European Journal of Epidemiology

Volumn 19, Issue 2, 2004, Pages 101-108

  Njajou, Omer T ^a   Alizadeh, Behrooz Z ^a   Van Duijn, Cornelia M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Genetic epidemiology; Hemochromatosis; HFE; Penetrance; Screening

Indexed keywords

CAUCASIAN; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; EARLY DIAGNOSIS; GENE; GENE MUTATION; GENETIC EPIDEMIOLOGY; GENETIC SCREENING; GENOTYPE; HEMOCHROMATOSIS; HFE GENE; HIGH RISK POPULATION; HOMOZYGOSITY; HUMAN; IRON BLOOD LEVEL; PHENOTYPE; PHLEBOTOMY; RECESSIVE INHERITANCE; REVIEW; SCREENING TEST; SOCIAL PSYCHOLOGY;

FEMALE; FORECASTING; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HEMOCHROMATOSIS; HUMANS; MALE; PREVALENCE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; WORLD HEALTH ORGANIZATION;

EID: 1642380179     PISSN: 03932990     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:EJEP.0000017664.96394.b9     Document Type: Review

References (74)

1. Adams P, Brissot P, Powell LW. EASL International Consensus Conference on Haemochromatosis. J Hepatol 2000; 33: 485-504.
2. Powell LW, Leggett BA, Crawford DHG. Hemochromatosis and other iron storage disorders. In: Schiff ER, Sorrel MF, Maddrey WC (eds), Schiff's diseases of the liver. Philadelphia: Lippincott-Raven, 1999: 1107-1130.
3. Edwards CQ, Griffen LM, Goldgar D, Drummond C, Skolnick MH, Kushner JP. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988; 318: 1355-1362.
4. Leggett BA, Halliday JW, Brown NN, Bryant S, Powell LW. Prevalence of haemochromatosis amongst asymptomatic Australians. Br J Haematol 1990; 74: 525-530.
5. Baer DM, Simons JL, Staples RL, Rumore GJ, Morton CJ. Hemochromatosis screening in asymptomatic ambulatory men 30 years of age and older. Am J Med 1995; 98: 464-468.
6. Cardoso EM, Stal P, Hagen K, et al. HFE mutations in patients with hereditary haemochromatosis in Sweden. J Intern Med 1998; 243: 203-208.
7. Powell L, Jazwinska E, Halliday J. Primary iron overload. In: Brock J, Halliday J, Pippard M, Powell L (eds), Iron metabolism in health and disease. London: Saunders, 1994: 227-270.
8. Witte DL, Crosby WH, Edwards CQ, Fairbanks VF, Mitros FA. Practice guideline development task force of the College of American Pathologists. Hereditary hemochromatosis. Clin Chim Acta 1996; 245: 139-200.
9. Finch S, Finch C. Idiopathic hemochromatosis, an iron storage disease. A: Iron metabolism in hemochromatosis. Medicine 1955; 34: 381-430.
10. Scheuer P, Williams R, Muir A. Hepatic pathology in relatives of patients with hemochromatosis. J Pathol Bacteriol 1962; 84: 53-64.
11. Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology 1986; 6: 24-29.
12. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399-408.
13. Powell LW. Diagnosis of hemochromatosis. Semin Gastrointest Dis 2002; 13: 80-88.
14. Sheldon J. Hemochromatosis. London: Oxford University Press; 1935.
15. Saddi R, Feingold J. Hemochromatose idiopathique. Maladie recessive autosomique. Rev Fr Etud Clin Biol 1969; 14: 238-251.
16. Saddi R, Feingold J. Idiopathic haemochromatosis: An autosomal recessive disease. Clin Genet 1974; 5: 234-241.
17. Simon M, Alexandre JL, Bourel M, Le Marec B, Scordia C. Heredity of idiopathic haemochromatosis: A study of 106 families. Clin Genet 1977; 11: 327-341.
18. Simon M, Hespel JP, Fauchet R, et al. Heredite recessive de l'hemochromatose idiopathique: deux observations de transmission pseudo-dominante reconnue comme recessive par l'etude de la surcharge en fer et des genotypes HLA dans les familles. Nouv Presse Med 1979; 8: 421-424.
19. Simon M, Alexandre JL, Fauchet R, Genetet B, Bourel M. The genetics of hemochromatosis. Prog Med Genet 1980; 4: 135-168.
20. Barton JC, Shih WW, Sawada-Hirai R, et al. Genetic and clinical description of hemochromatosis probands and heterozygotes: Evidence that multiple genes linked to the major histocompatibility complex are responsible for hemochromatosis. Blood Cells Mol Dis 1997; 23: 135-145.
21. Brissot P, Moirand R, Jouanolle AM, et al. A genotypic study of 217 unrelated probands diagnosed as 'genetic hemochromatosis' on 'classical' phenotypic criteria. J Hepatol 1999; 30: 588-593.
22. Moirand R, Jouanolle AM, Brissot P, Le Gall JY, David V, Deugnier Y. Phenotypic expression of HFE mutations: A French study of 1110 unrelated iron-overloaded patients and relatives. Gastroenterology 1999; 116: 372-377.
23. Whitfield JB, Cullen LM, Jazwinska EC, et al. Effects of HFE C282Y and H63D polymorphisms and polygenic background on iron stores in a large community sample of twins. Am J Hum Genet 2000; 66: 1246-1258.
24. Beutler E, Gelbart T, West C, et al. Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis 1996; 22: 187-194.
25. Borot N, Roth M, Malfroy L, et al. Mutations in the MHC class I-like candidate gene for hemochromatosis in French patients. Immunogenetics 1997; 45: 320-324.
26. Jazwinska EC, Powell LW. Hemochromatosis and 'HLA-H': Definite! Hepatology 1997; 25: 495-496.
27. Pointon JJ, Wallace D, Merryweather-Clarke AT, Robson KJ. Uncommon mutations and polymorphisms in the hemochromatosis gene. Genet Test 2000; 4: 151-161.
28. Parkkila S, Waheed A, Britton RS, et al. Immunohistochemistry of HLA-H, the protein defective in patients with hereditary hemochromatosis, reveals unique pattern of expression in gastrointestinal tract. Proc Natl Acad Sci USA 1997; 94: 2534-2539.
29. Lebron JA, Bennett MJ, Vaughn DE, et al. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell 1998; 93: 111-123.
30. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997; 34: 275-278.
31. Hanson EH, Imperatore G, Burke W. HFE gene and hereditary hemochromatosis: A HuGE review. Human Genome Epidemiology. Am J Epidemiol 2001; 154: 193-206.
32. Jouanolle AM, Gandon G, Jezequel P, et al. Haemochromatosis and HLA-H. Nat Genet 1996; 14: 251-252.
33. Cazzola M, Ascari E, Barosi G, et al. Juvenile idiopathic haemochromatosis: A life-threatening disorder presenting as hypogonadotropic hypogonadism. Hum Genet 1983; 65: 149-154.
34. Camaschella C, Roetto A, Cicilano M, et al. Juvenile and adult hemochromatosis are distinct genetic disorders. Eur J Hum Genet 1997; 5: 371-375.
35. Charlton RW, Abrahams C, Bothwell TH. Idiopathic hemochromatosis in young subjects. Clinical, pathological, and chemical findings in four patients. Arch Pathol 1967; 83: 132-140.
36. Cazzola M, Cerani P, Rovati A, Iannone A, Claudiani G, Bergamaschi G. Juvenile genetic hemochromatosis is clinically and genetically distinct from the classical HLA-related disorder. Blood 1998; 92: 2979-2981.
37. Kelly AL, Rhodes DA, Roland JM, Schofield P, Cox TM. Hereditary juvenile haemochromatosis: A genetically heterogeneous life-threatening iron-storage disease. QJM 1998; 91: 607-618.
38. Roetto A, Totaro A, Cazzola M, et al. Juvenile hemochromatosis locus maps to chromosome 1q. Am J Hum Genet 1999; 64: 1388-1393.
39. Papanikolaou G, Papaioannou M, Politou M, et al. Genetic heterogeneity underlies juvenile hemochromatosis phenotype: Analysis of three families of northern greek origin. Blood Cells Mol Dis 2002; 29: 168-173.
40. Camaschella C, Roetto A, Cali A, et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. Nat Genet 2000; 25: 14-15.
41. Roetto A, Daraio F, Alberti F, et al. Hemochromatosis due to mutations in transferrin receptor 2. Blood Cells Mol Dis 2002; 29: 465-470.
42. Pietrangelo A, Montosi G, Totaro A, et al. Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene. N Engl J Med 1999; 341: 725-732.
43. Montosi G, Donovan A, Totaro A, et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest 2001; 108: 619-623.
44. Njajou OT, Vaessen N, Joosse M, et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat Genet 2001; 28: 213-214.
45. Devalia V, Carter K, Walker AP, et al. Autosomal dominant reticuloendothelial iron overload associated with a 3-base pair deletion in the ferroportin I gene (SLC11A3). Blood 2002; 100: 695-697.
46. Roetto A, Merryweather-Clarke AT, Daraio F, et al. A valine deletion of ferroportin 1: A common mutation in hemochromastosis type 4. Blood 2002; 100: 733-734.
47. Wallace DF, Pedersen P, Dixon JL, et al. Novel mutation in ferroportin 1 is associated with autosomal dominant hemochromatosis. Blood 2002; 100: 692-694.
48. Townsend A, Drakesmith H. Role of HFE in iron metabolism, hereditary haemochromatosis, anaemia of chronic disease, and secondary iron overload. Lancet 2002; 359: 786-790.
49. Kato J, Fujikawa K, Kanda M, et al. A mutation, in the iron-responsive element of H ferritin mRNA, causing autosomal dominant iron overload. Am J Hum Genet 2001; 69: 191-197.
50. Baer D. Hereditary iron overload and African Americans. Am J Med 1996; 101: 5-8.
51. Gangaidzo IT, Moyo VM, Saungweme T, et al. Iron overload in urban Africans in the 1990s. Gut 1999; 45: 278-283.
52. Beutler E, Gelbart T. HLA-H mutations in the Ashkenazi Jewish population. Blood Cells Mol Dis 1997; 23: 95-98.
53. Burke W, Thomson E, Khoury MJ, et al. Hereditary hemochromatosis: Gene discovery and its implications for population-based screening. JAMA 1998; 280: 172-178.
54. Edwards CQ, Kushner JP. Screening for hemochromatosis. N Engl J Med 1993; 328: 1616-1620.
55. Haddow JE, Ledue TB. Preventing manifestations of hereditary haemochromatosis through population based screening. J Med Screen 1994; 1: 16-21.
56. Bradley LA, Haddow JE, Palomaki GE. Population screening for haemochromatosis: A unifying analysis of published intervention trials. J Med Screen 1996; 3: 178-184.
57. Wilson J, Junger G. The principle and practise of screening for disease. Public Health Papers WHO 1968; 34: 26-29.
58. US preventive services task force. Guide to Clinical Preventive Services: Report of the US Preventive Services Task Force. 2nd edn. Baltimore, MD, 1969, pp. 231-246.
59. Adams PC, Gregor JC, Kertesz AE, Valberg LS. Screening blood donors for hereditary hemochromatosis: Decision analysis model based on a 30-year database. Gastroenterology 1995; 109: 177-188.
60. Tavill A. Screening for hemochromatosis: Phenotyping or genotyping or both? Am J Gastroenterol 1999; 94: 1430-1433.
61. Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G→ A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002; 359: 211-218.
62. Burt MJ, George PM, Upton JD, et al. The significance of haemochromatosis gene mutations in the general population: Implications for screening. Gut 1998; 43: 830-836.
63. Adams P, Valberg L. Screening blood donors fot hereditery hemochromatosis: Decision analysis model comparing genotyping to phenotyping. Am J Gastroenteroly 1999; 94: 1593-1600.
64. Phatak PD, Guzman G, Woll JE, Robeson A, Phelps CE. Cost-effectiveness of screening for hereditary hemochromatosis. Arch Intern Med. 1994; 11(154): 769-776; Allen K, Warner B, Delatyecki M. Clinical hemochromatosis in HFE mutation carriers. Lancet 2002; 360: 412-413.
65. Phatak PD, Guzman G, Woll JE, Robeson A, Phelps CE. Cost-effectiveness of screening for hereditary hemochromatosis. Arch Intern Med. 1994; 11(154): 769-776; Allen K, Warner B, Delatyecki M. Clinical hemochromatosis in HFE mutation carriers. Lancet 2002; 360: 412-413.
66. Khoury MJ. Human genome epidemiology: Translating advances in human genetics into population-based data for medicine and public health. Genet Med 1999; 1: 71-73.
67. Holtzman NA, Marteau TM. Will genetics revolutionize medicine? N Engl J Med 2000; 343: 141-144.
68. Njajou OT, Houwing-Duistermaat JJ, Osborne R, et al. A population-based study of the effect of the HFE C282Y and H63D mutations on iron metabolism. Eur J Hum Gen 2003; 11: 225-231.
69. Vogelstein B, Kinzler KW. The genetic basis of human cancer. New York: McGraw-Hill, 1998.
70. Bassett ML, Wilson SR, Cavanaugh JA. Penetrance of HFE-related hemochromatosis in perspective. Hepatology 2002; 36: 500-503.
71. Cox T, Rochette J, Camaschella C, Walker A, K R. Clinical hemochromatosis in HFE mutation carriers. Lancet 2002; 360: 412.
72. Poullis A, Moodie SJ, Maxwell JD. Clinical hemochromatosis in HFE mutation carriers. The Lancet 2002; 360: 411.
73. Njajou OT, Hollander M, Koudstaal PJ, et al. Mutations in HFE gene and stroke. Stroke 2002; 33: 2363-2366.
74. Njajou OT, Alizadeh BZ, Vaessen N, et al. The role of hemochromatosis C282Y and H63D mutations in type 2 diabetes. Diabetes Care 2002; 25: 2112-2113.